Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated at StockNews.com

Research analysts at StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report issued on Tuesday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

Shares of NASDAQ EGRX opened at $1.50 on Tuesday. The business has a 50-day moving average of $0.79 and a 200-day moving average of $1.72. Eagle Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $6.81.

Hedge Funds Weigh In On Eagle Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Jacobs Levy Equity Management Inc. bought a new stake in shares of Eagle Pharmaceuticals during the 3rd quarter worth $453,000. Jane Street Group LLC purchased a new stake in Eagle Pharmaceuticals during the third quarter valued at about $96,000. DGS Capital Management LLC lifted its stake in Eagle Pharmaceuticals by 44.9% during the third quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock worth $268,000 after purchasing an additional 22,239 shares during the last quarter. Creative Planning purchased a new position in shares of Eagle Pharmaceuticals in the 3rd quarter worth about $59,000. Finally, RBF Capital LLC increased its position in shares of Eagle Pharmaceuticals by 11.7% during the 3rd quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock valued at $534,000 after purchasing an additional 14,991 shares during the last quarter. Institutional investors own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.